{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T23:03:05Z","timestamp":1780095785809,"version":"3.54.0"},"reference-count":22,"publisher":"Georg Thieme Verlag KG","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dtsch Med Wochenschr"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Was ist neu?<\/jats:title>\n                  <jats:p>Parallel zur weltweit steigenden Inzidenz von Krebserkrankungen nimmt die Zahl kritisch kranker onkologischer Patient*innen mit potenziellem intensivmedizinischem Versorgungsbedarf zu. Insbesondere Nebenwirkungen im Rahmen von Chemotherapie, h\u00e4matopoetischer Stammzelltransplantation (HSCT) und Immuntherapien erfordern zunehmend intensivmedizinische Interventionen. Obgleich die erhebliche Heterogenit\u00e4t dieser Patientengruppe pauschale Aussagen erschwert, belegen Studien, dass kritisch kranke onkologische Patient*innen trotz schwerer Krankheitsverl\u00e4ufe durchaus eine g\u00fcnstige Prognose hinsichtlich \u00dcberleben und funktioneller Erholung haben k\u00f6nnen.<\/jats:p>\n                  <jats:p>ARF ist mit die h\u00e4ufigste Ursache f\u00fcr eine intensivmedizinische Aufnahme onkologischer Patient*innen. Das therapeutische Vorgehen ist komplex und insbesondere im Kontext bestehender Therapiebegrenzungen nicht standardisiert. Nicht invasive Atemunterst\u00fctzung wie High-Flow-Therapie (HFNO) oder nicht invasive Ventilation (NIV) k\u00f6nnen in selektionierten F\u00e4llen Vorteile bieten, setzen jedoch eine engmaschige \u00dcberwachung und rasche Eskalationsbereitschaft voraus.<\/jats:p>\n                  <jats:p>Innovative immunonkologische Therapieans\u00e4tze haben das onkologische Behandlungsspektrum erheblich erweitert, sind aber mit spezifischen, teils lebensbedrohlichen Nebenwirkungen assoziiert. Hierzu z\u00e4hlen insbesondere das durch CAR-T Zellen und sog. T-Zell-Engager verursachte Zytokin-Freisetzungssyndrom (CRS) und das das mit Immun-Effektorzellen assoziierte Neurotoxizit\u00e4tssyndrom (ICANS) sowie weitere immunvermittelte Nebenwirkungen (irAEs) im Zusammenhang mit Immuncheckpoint-Inhibitoren (ICI). Diese Komplikationen erfordern eine strukturierte Diagnostik, ein interdisziplin\u00e4res Management sowie den fr\u00fchzeitigen Einsatz immunmodulierender Therapien.<\/jats:p>","DOI":"10.1055\/a-2676-1845","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T22:38:29Z","timestamp":1780094309000},"page":"612-616","source":"Crossref","is-referenced-by-count":0,"title":["Intensivmedizinische Versorgung im Rahmen onkologischer Therapie"],"prefix":"10.1055","volume":"151","author":[{"given":"Hans Joachim","family":"Stemmler","sequence":"additional","affiliation":[{"name":"LMU M\u00fcnchen, GERMANY","place":["M\u00fcnchen"],"department":["Medizinische Klinik und Poliklinik III"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Fraccaroli","sequence":"additional","affiliation":[{"name":"LMU M\u00fcnchen, GERMANY","place":["M\u00fcnchen"],"department":["Medizinische Klinik und Poliklinik III"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"von Bergwelt-Baildon","sequence":"additional","affiliation":[{"name":"LMU M\u00fcnchen, GERMANY","place":["M\u00fcnchen"],"department":["Medizinische Klinik und Poliklinik III"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1007\/s00134-021-06502-2","article-title":"Critical illness in patients with hematologic malignancy: a population-based cohort study","volume":"47","author":"BL Ferreyro","year":"2021","journal-title":"Intensive Care Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2025.101306","article-title":"Advances in the critical care management for patients with hematological malignancies","volume":"74","author":"E Azoulay","year":"2025","journal-title":"Blood Rev"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s00063-012-0179-x","article-title":"Infections in hemato-oncology patients in intensive care. An interdisciplinary challenge","volume":"108","author":"M Kochanek","year":"2013","journal-title":"Med Klin Intensivmed Notfmed"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1007\/s00063-019-0594-3","article-title":"Prevalence of cancer patients in German intensive care units","volume":"115","author":"M Kochanek","year":"2020","journal-title":"Med Klin Intensivmed Notfmed"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"2810","DOI":"10.1200\/JCO.2012.47.2365","article-title":"Outcomes of critically ill patients with hematologic malignancies: prospective multicenter data from France and Belgium \u2013 a groupe de recherche respiratoire en reanimation onco-hematologique study","volume":"31","author":"E Azoulay","year":"2013","journal-title":"J Clin Oncol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s00134-024-07349-z","article-title":"Long-term survival and functional outcomes of critically ill patients with hematologic malignancies: a Canadian multicenter prospective study","volume":"50","author":"L Munshi","year":"2024","journal-title":"Intensive Care Med"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"3855","DOI":"10.1007\/s00520-019-05226-w","article-title":"Characteristics and outcomes of patients with solid tumors receiving chemotherapy in the intensive care unit","volume":"28","author":"DJ Shaz","year":"2020","journal-title":"Support Care Cancer"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1159\/000520097","article-title":"Long-Term Outcomes and Prognostic Factors of Patients with Metastatic Solid Tumors Admitted to the Intensive Care Unit","volume":"100","author":"S Hautecloque-Rayz","year":"2022","journal-title":"Oncology"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"957","DOI":"10.3904\/kjim.2024.054","article-title":"Short-term and long-term outcomes of critically ill patients with solid malignancy: a retrospective cohort study","volume":"39","author":"SY Lee","year":"2024","journal-title":"Korean J Intern Med"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1016\/j.chest.2020.05.602","article-title":"Respiratory Mechanics and Outcomes in Immunocompromised Patients With ARDS: A Secondary Analysis of the EFRAIM Study","volume":"158","author":"A Demoule","year":"2020","journal-title":"Chest"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1007\/s00134-025-08113-7","article-title":"Acute respiratory distress syndrome in patients with cancer: the YELENNA prospective multinational observational cohort study","volume":"51","author":"P Schellongowski","year":"2025","journal-title":"Intensive Care Med"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1001\/jama.2018.14282","article-title":"Effect of High-Flow Nasal Oxygen vs Standard Oxygen on 28-Day Mortality in Immunocompromised Patients With Acute Respiratory Failure: The HIGH Randomized Clinical Trial","volume":"320","author":"E Azoulay","year":"2018","journal-title":"JAMA"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1007\/s11739-024-03777-3","article-title":"Efficacy of high-flow nasal oxygen therapy in cancer patients with concurrent acute hypoxemic respiratory failure: a retrospective propensity score study","volume":"20","author":"Y Ge","year":"2025","journal-title":"Intern Emerg Med"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13613-016-0151-7","article-title":"High-flow nasal cannula oxygen therapy versus noninvasive ventilation in immunocompromised patients with acute respiratory failure: an observational cohort study","volume":"6","author":"R Coudroy","year":"2016","journal-title":"Ann Intensive Care"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.14712","article-title":"The success of non-invasive mechanical ventilation in lung cancer patients with respiratory failure","volume":"75","author":"D Kizilgoz","year":"2021","journal-title":"Int J Clin Pract"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1007\/s00063-021-00823-2","article-title":"Patient self-inflicted lung injury (P-SILI) : From pathophysiology to clinical evaluation with differentiated management","volume":"116","author":"B Neetz","year":"2021","journal-title":"Med Klin Intensivmed Notfmed"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1164\/rccm.201606-1306OC","article-title":"Noninvasive Ventilation of Patients with Acute Respiratory Distress Syndrome. Insights from the LUNG SAFE Study","volume":"195","author":"G Bellani","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s00063-025-01273-w","article-title":"Acute respiratory distress syndrome-quo vadis: Innovative and individualized treatment approaches","volume":"120","author":"N Buchtele","year":"2025","journal-title":"Med Klin Intensivmed Notfmed"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1164\/rccm.202009-3575OC","article-title":"Survival in Immunocompromised Patients Ultimately Requiring Invasive Mechanical Ventilation: A Pooled Individual Patient Data Analysis","volume":"204","author":"G Dumas","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1055\/a-1303-8708","article-title":"Practical aspects of the application of CAR T cells and management of their toxicities","volume":"146","author":"V Bucklein","year":"2021","journal-title":"Dtsch Med Wochenschr"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1093\/annonc\/mdx286","article-title":"Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review","volume":"28","author":"L Khoja","year":"2017","journal-title":"Ann Oncol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"78","DOI":"10.3322\/caac.21702","article-title":"Critical care management of chimeric antigen receptor T-cell therapy recipients","volume":"72","author":"A Shimabukuro-Vornhagen","year":"2022","journal-title":"CA Cancer J Clin"}],"container-title":["DMW - Deutsche Medizinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2676-1845.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T22:38:33Z","timestamp":1780094313000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2676-1845"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":22,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2026,5,29]]},"published-print":{"date-parts":[[2026,6]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2676-1845","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0012-0472","1439-4413"],"issn-type":[{"value":"0012-0472","type":"print"},{"value":"1439-4413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]}}}